Alzheimer's patients could lose out on two groundbreaking new drugs because the NHS is ... the first symptoms of dementia emerge, such as memory loss, or confusion. Donanemab and lecanemab are ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

A recent study led by researchers at the University of Southern California (USC) has uncovered a connection between mild ...

The federal Food & Drug Administration has approved two new Alzheimer’s medications ... antibody infusions for slowing memory and thinking loss. The FDA approved Lecanemab (Leqembi) in July ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

In addition to treating Alzheimer's disease, which affects roughly 6.9 million people over age 65 and has no known cure, VU319 has shown the potential to treat memory loss in schizophrenia ...